← Back to Search

Monoclonal Antibodies

KN026 for Gastric Cancer

Phase 1

Waitlist Available

Research Sponsored by Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up throughout the duration of the study; up to 2 years

Awards & highlights

Study Summary

This trial is testing a new drug, KN026, to see if it is safe and works well against HER2 positive advanced breast and gastric cancer.

Eligible Conditions

Gastric Cancer
Breast Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ throughout the duration of the study; up to 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~throughout the duration of the study; up to 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and throughout the duration of the study; up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

The proportion of patients experiencing dose limiting toxicities

Secondary outcome measures

Frequency and titer of anti-KN026 antibody

Maximum observed serum concentration (Cmax) of KN026

Percentage of participants with adverse events (AEs), serious adverse events (SAEs) and AEs of special interest

+3 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: KN026Experimental Treatment1 Intervention

Patient will be intravenously administrated with one dose of KN026. Dosing interval may be adjusted during the study based on emerging data from this trial and/or from other trial.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

KN026

2018

Completed Phase 1

~70

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Jiangsu Alphamab Biopharmaceuticals Co., LtdLead Sponsor

26 Previous Clinical Trials

3,009 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still spots available for recruitment in this research endeavor?

"This clinical trial, posted on June 18th 2019 and last updated November 16th 2021, is not accepting patients at this time. However, data hosted on clinicialtrials.gov reveals that there are 2601 other trials actively seeking participants."

Answered by AI